Publication | Closed Access
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
265
Citations
26
References
2006
Year
Hematological MalignancyCytogeneticsMedicineGeneticsGenetic DisorderHematologyPathologyChromosome 13Poor PrognosisCancer GeneticsMolecular DiagnosticsOncologyPhase 2Chromosome 9Cancer ResearchHealth Sciences
| Year | Citations | |
|---|---|---|
Page 1
Page 1